MK-677 body recomposition claims: what 22 days actually shows
Quick answer
MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist that stimulates endogenous GH and IGF-1 secretion; it does not contain exogenous growth hormone. Clinical studies document real effects on appetite, slow-wave sleep, lean mass, and bone markers, but also flag insulin resistance and fluid retention as adverse effects with sustained use. It is not FDA-approved and should only be used under clinical supervision with appropriate baseline and follow-up lab work.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @liftsbyfahd actually say?
In a 22-day progress update, Fahed claimed MK-677 "increases your appetite like crazy," improves sleep, and aids recovery. He described it as containing "growth hormone," which he said raises what he called "TH" and improves recovery. He framed the compound's entire purpose as bulking, sleep, and recovery, and told viewers that anyone reporting anything beyond that was scammed or lying.
He ran it for 22 days and planned a 30-day total run. That framing is shorter than most research protocols and shorter than the cycles most clinical literature uses. It is worth noting from the start.
Does the science back this up?
Partially, but the mechanism is being described incorrectly. MK-677 does not "have growth hormone in it." It is a ghrelin receptor agonist and a growth hormone secretagogue, meaning it stimulates the pituitary to release more of your own GH. That is a real and documented effect. Nass et al. (2008, Journal of Clinical Endocrinology and Metabolism) confirmed sustained GH and IGF-1 elevation in older adults over two years of MK-677 use. The appetite effect is also real: ghrelin is the hunger hormone, so agonizing its receptor does reliably increase appetite, as shown in Murphy et al. (1998, Journal of Endocrinology).
The sleep claim has some support too. Frieboes et al. (1995, Neuroendocrinology) found that ghrelin-pathway stimulation increases slow-wave sleep in healthy men, which is the deep restorative stage associated with GH pulse and recovery. So the sleep-recovery connection is not invented. His description of the mechanism, though, is wrong.
What did they get wrong (or right)?
The biggest factual error: MK-677 does not "have growth hormone in it." It signals your body to make more of its own. That distinction matters clinically and legally. Compounds that contain exogenous GH carry different risk profiles, require injection, and are regulated differently. Conflating the two could lead viewers to assume MK-677 carries the same potency, benefits, or risks as injectable HGH, which is not accurate.
His dismissal of other effects is also overconfident. MK-677 has shown meaningful effects on lean mass retention (Svensson et al., 1998, Journal of Clinical Endocrinology and Metabolism), bone mineral density markers, and nitrogen balance. Calling anyone who notices these effects "lying or scammed" is not science, it is overreach.
What he got right: appetite increase is real, sleep quality improvement is documented, and his acknowledgment that appetite was hard to manage in weeks one and two is consistent with what the literature describes about the initial ghrelin surge.
What should you actually know?
MK-677 is not approved by the FDA for any use. It is classified as an investigational compound, and while it has been studied in clinical trials for muscle wasting, GH deficiency, and aging, it has not cleared regulatory review for any of those indications. The risk profile includes fluid retention, increased fasting glucose, and potential insulin resistance with longer-term use. Nass et al. (2008) flagged elevated fasting glucose as a meaningful adverse effect in their two-year cohort.
A 30-day self-directed run without labs or clinical oversight also skips the most important monitoring window. IGF-1 elevation without baseline testing means you have no idea where you started or where you are going. Anyone considering MK-677 should have a conversation with a licensed provider who can order appropriate labs, not structure a cycle based on a TikTok comment section.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For MK-677 body recomposition claims: what 22 days actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis
Used for PCOS pages comparing metabolic and weight-management approaches.
PubMed
The efficacy and safety of GLP-1 agonists in PCOS women living with obesity
Supports PCOS, obesity, and hormonal-regulation context.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
MK-677 body recomposition claims: what 22 days actually shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist that stimulates endogenous GH and IGF-1 secretion; it does not contain exogenous growth hormone.
FormBlends verdict
MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist that stimulates endogenous GH and IGF-1 secretion; it does not contain exogenous growth hormone. Clinical studies document real effects on appetite, slow-wave sleep, lean mass, and bone markers, but also flag insulin resistance and fluid retention as adverse effects with sustained use. It is not FDA-approved and should only be used under clinical supervision with appropriate baseline and follow-up lab work.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist that stimulates endogenous GH and IGF-1 secretion; it does not contain exogenous growth hormone. Clinical studies document real effects on appetite, slow-wave sleep, lean mass, and bone markers, but also flag insulin resistance and fluid retention as adverse effects with sustained use. It is not FDA-approved and should only be used under clinical supervision with appropriate baseline and follow-up lab work.
- MK-677 is a ghrelin receptor agonist, not a growth hormone product. It signals your pituitary to release more of your own GH, a distinction that matters for both safety and legal classification.
- Appetite increases are real and documented. Ghrelin receptor agonism is a well-established hunger signal driver (Murphy et al., 1998, Journal of Endocrinology).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- MK-677 is a ghrelin receptor agonist, not a growth hormone product. It signals your pituitary to release more of your own GH, a distinction that matters for both safety and legal classification.
- Appetite increases are real and documented. Ghrelin receptor agonism is a well-established hunger signal driver (Murphy et al., 1998, Journal of Endocrinology).
- Slow-wave sleep improvement has clinical support. Frieboes et al. (1995, Neuroendocrinology) found ghrelin-pathway stimulation increases restorative deep sleep stages in healthy men.
- Insulin resistance and elevated fasting glucose are documented risks. Nass et al. (2008, JCEM) flagged these as meaningful adverse effects in a two-year cohort, making unsupervised use a real concern.
- MK-677 is not FDA-approved for any indication. It remains an investigational compound and its legal status for personal use varies by jurisdiction.
- A 30-day self-directed run without baseline labs for IGF-1 and fasting glucose provides no safety monitoring and no way to assess actual response or risk.
- Lean mass and bone density effects have been studied (Svensson et al., 1998, JCEM), meaning Fahed's claim that any effect beyond sleep and appetite equals a scam is not supported by clinical literature.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
liftsbyfahd · TikTok creator
265.9K views on this video
22 DAYS BABYYY (gear next?) #gym #viral #mk677 #gymtok #fitness
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by liftsbyfahd, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.